CA-based ArteraAI secures additional $20million in funding. Prosperity7 Ventures, Walden Catalyst Ventures, Wilson Sonsini Goodrich & Rosati, Singapore-based global investor EDBI, investors Navin Chaddha, Rajiv Khemani (AISpace VC), and Andrew & Elliott Tan (A&E Investment LLC) participated in the round.
The funds will be used by the company for testing, commercial growth, and international expansion. Precision medicine startup ArteraAI, led by CEO Andre Esteva, is creating AI testing to customize cancer treatment and offer prognostic and predictive outcomes for patients with locally advanced prostate cancer.
Read also – CA-based LightBeam.ai Secures $17.8Million in Funding
Prostate Test by ArteraAI. Its multimodal artificial intelligence (MMAI) biomarker test makes use of an algorithm that analyzes digital images obtained from a biopsy and gains knowledge from the clinical information provided by the patient.
The AI has been verified in numerous Phase 3 randomized trials and uses this data to forecast a patient’s prognosis and whether they would benefit from a specific therapy.
Our CLIA-certified laboratory in Jacksonville, Florida offers the test clinically.
Read also – CA-based Perelel Secures $6Million in Series A Round Funding
Andre Esteva said: “The infusion of this additional funding is a crucial catalyst, propelling ArteraAI forward in its mission to personalize cancer therapy through AI-enabled predictive and prognostic tests.”
About ArteraAI
ArteraAI , In cases of localized prostate cancer, their AI can predict patient outcomes and tailor treatment. AI biomarkers that are predictive and prognostic were developed through five Phase III randomized trials.
Read also – WA-based Proniras Secures $4.65Million in Series B Round Funding
